300026 Tianjin Chase Sun Pharmaceutical
- 3.83
- +0.01+0.26%
Tianjin Chase Sun Pharmaceutical News
Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The subdued market reaction suggests that Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) recent earnings didn't contain any surprises. We think that investors are worried about some weaknes
Not Many Are Piling Into Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Just Yet
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 31x, you may consider Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) as an attractive investment with
Red Sun Pharmaceutical (300026.SZ): Yao Xiaoqing resigns as chairman
Gelonghui, April 1, 丨 Hongri Pharmaceutical (300026.SZ) announced that the board of directors of the company recently received a written application for resignation from Mr. Yao Xiaoqing, the chairman of the company. Mr. Yao Xiaoqing applied to resign as the company's legal representative, chairman, director and relevant positions in the special committee of the board of directors due to personal work reasons. After his resignation, he no longer held any position in the company.
Hongri Pharmaceutical (300026.SZ): The subsidiary looks forward to the pharmaceutical industry selling esprolol hydrochloride raw materials
Gelonghui, March 29丨An investor asked Hongri Pharmaceutical (300026.SZ) on the investor interactive platform. “Do your company and subsidiaries have esprolol hydrochloride APIs and corresponding formulations?” The company replied that the company's subsidiary expects the pharmaceutical industry to sell esprolol hydrochloride APIs.
Hongri Pharmaceutical (300026.SZ): Ketorolac tromethanol injection is currently under CDE review
Gelonghui, March 29丨An investor asked Hongri Pharmaceutical (300026.SZ) on the investor interactive platform, “The consistency evaluation of your company's ketorolac tromethotriol injection completed various technical reviews at the end of August 2023. Why hasn't it been approved until now?” The company replied that ketorolac and tromethotriol injections are currently under CDE review.
Red Sun Pharmaceutical (300026.SZ): Net profit for 2023 will drop 18.84% to 507 million yuan, and plans to distribute 10 to 0.3 yuan
Gelonghui March 28 | Hongri Pharmaceutical (300026.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 6.109 billion yuan, a year-on-year decrease of 8.14%; net profit attributable to shareholders of listed companies was 507 million yuan. , a year-on-year decrease of 18.84%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 376 million yuan, a year-on-year decrease of 34.20%; basic earnings per share were 0.17 yuan; it is proposed to distribute a cash dividend of 0.30 yuan (tax included) for every 10 shares to all shareholders.
The One-year Shareholder Returns and Company Earnings Persist Lower as Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Stock Falls a Further 6.1% in Past Week
The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. That downside
Hongri Pharmaceutical (300026.SZ): Chase Group's shareholding ratio fell below 5%
Gelonghui, March 19 | Hongri Pharmaceutical (300026.SZ) announced that the company recently received the “Simplified Equity Change Report” issued by Chase Group. I learned that Chase Group reduced its holdings (including passive holdings reduction and judicial auctions) of the company's shares in total 143,171,029 shares (including passive holdings reduction and judicial auctions) from July 9, 2020 to the date of disclosure of the report from July 9, 2020 to the date of disclosure of the report, accounting for 4.76577% of the company's total share capital. After this change in equity, the shares of the company held by Chase Group fell from 293,376,722 shares to 150,20
Zheng Dan, vice chairman, director and general manager of Hongri Pharmaceutical (300026.SZ) retires
Hongri Pharmaceutical (300026.SZ) announced that the board of directors of the company recently received Zheng Dan from the vice chairman, director and general manager...
Hongri Pharmaceutical (300026.SZ) Performance Report: Net profit of 529 million yuan in 2023 fell 15.22% year on year
Gelonghui, Feb. 29 | Hongri Pharmaceutical (300026.SZ) announced its 2023 annual results report. In 2023, the company's total revenue was 6.127 billion yuan, down 7.86% from the same period last year; total profit of 629 million yuan, down 12.19% year on year; net profit attributable to shareholders of listed companies was 529 million yuan, down 15.22% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 398 million yuan; basic earnings per share were 0.18 yuan.
Chase Group, the majority shareholder of Hongri Pharmaceuticals (300026.SZ), reduced its holdings by 30.22 million shares
Hongri Pharmaceutical (300026.SZ) announced that Tianjin Datong Investment Group Co., Ltd., the shareholder of the company holds more than 5% of the shares (...
Should Weakness in Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) has had a rough three months with its share price down 14%. However, stock prices are usually driven by a company's financials over the long term, w
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
Hongri Pharmaceutical (300026.SZ) issued a pre-reduction. Net profit is expected to be 502 million yuan to 538 million yuan in 2023, a year-on-year decrease of 13.82% to 19.58%
Hongri Pharmaceutical (300026.SZ) disclosed its 2023 annual results forecast. The company is expected to belong to listed company shares...
Individual Investors Invested in Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Copped the Brunt of Last Week's CN¥391m Market Cap Decline
Key Insights Tianjin Chase Sun PharmaceuticalLtd's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 17 inve
Chase Group, a shareholder of Hongri Pharmaceutical (300026.SZ), passively reduced its holdings of the company by 1.12%
Hongri Pharmaceutical (300026.SZ) issued an announcement. As of the date of disclosure of the announcement, the company's shareholder Chase Group passively reduced its shareholding...
There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings
Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) price-to-earnings (or "P/E") ratio of 19.4x might make it look like a buy right now compared to the market in China, where around half of the c
Red Day Pharmaceutical (300026.SZ): Xuebijing injection continues to be included in the national medical insurance drug catalogue
Gelonghui December 13丨Hongri Pharmaceutical (300026.SZ) announced that according to the results of the 2023 contract renewal negotiations for the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023)” announced by the National Health Insurance Administration and the Ministry of Human Resources and Social Security on December 13, 2023, the blood purification injection produced by Tianjin Hongri Pharmaceutical Co., Ltd. was renewed according to current conditions and continued to be included in category B of the “National Medical Insurance Drug Catalogue”.
Red Day Pharmaceutical (300026.SZ): Chaosi electronic product wrist oximeter obtained 510 (k) certification from the US FDA
Glonghui December 13丨Hongri Pharmaceutical (300026.SZ) announced that recently, Beijing Chaosi Electronic Technology Co., Ltd. (“Chaosi Electronics”), a wholly-owned subsidiary of Tianjin Hongri Pharmaceutical Co., Ltd., received a notice from the U.S. Food and Drug Administration (US Food and Drug Administration, hereinafter referred to as “FDA”), and Chaosi Electronics has obtained 510 (k) certification from the US FDA.
Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) 7.9% CAGR Outpaced the Company's Earnings Growth Over the Same Five-year Period
Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make significant gains if you buy good quality businesses at the right price. For ex
Analysis
Price Target
No Data
